Quince Therapeutics, Inc. (QNCX) Net Income (Loss) Attributable to Parent USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Quince Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2024.
  • Quince Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$11.1 M, a 9.02% increase year-over-year.
  • Quince Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$30.3 M, a 28.4% increase year-over-year.
  • Quince Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$31.4 M, a 39.2% increase from 2022.
  • Quince Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$51.7 M, a 42.6% increase from 2021.
  • Quince Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$89.9 M, a 17% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$30.3 M -$11.1 M +$1.11 M +9.02% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$31.4 M -$8.89 M -$3.36 M -60.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$28 M -$5.35 M +$2.57 M +32.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$30.6 M -$4.89 M +$11.7 M +70.5% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 -$42.3 M -$12.3 M +$9.39 M +43.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$51.7 M -$5.53 M +$17.9 M +76.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$69.5 M -$7.92 M +$13.8 M +63.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$83.3 M -$16.6 M +$5.19 M +23.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$88.5 M -$21.6 M +$1.45 M +6.26% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$89.9 M -$23.4 M -$2.84 M -13.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 -$87.1 M -$21.7 M -$200 K -0.93% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$86.9 M -$21.8 M -$4.14 M -23.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$82.8 M -$23.1 M -$5.91 M -34.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$76.8 M -$20.6 M -$8.18 M -66% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 -$68.7 M -$21.5 M -$11.6 M -118% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 -$57 M -$17.6 M -$8.55 M -94.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 -$48.5 M -$17.2 M -$11.5 M -202% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$37 M -$12.4 M -$8.91 M -257% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$28.1 M -$9.86 M -$7.34 M -291% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$20.7 M -$9.06 M -$5.95 M -192% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$14.8 M -$5.68 M -$2.3 M -68.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$12.5 M -$3.47 M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 -$2.52 M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$3.11 M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$3.38 M Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.